Multiple sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. This activity is designed to help neurologists integrate the latest clinical evidence on disease-modifying therapies (DMTs) with patient needs and preferences to develop effective, individualized treatment plans. During this multimedia case-based activity, learners will balance the benefits and risks of MS treatment options to optimize patient management through shared decision-making. MS is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. The availability of DMT has revolutionized the care of patients with MS; however, more than a dozen DMTs are currently FDA-approved, with several more undergoing late-stage clinical trials. With no head-to-head trials of DMTs, clinicians are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. Clinical practice guidelines were released in early 2018 by the AAN, and many clinicians require education on the new recommendations. To address the multisystem nature of MS, clinicians must be prepared to coordinate care within a multidisciplinary team, and shared decision-making with a patient-centric approach is a critical component of effective care.
Patricia K. Coyle, MD
Professor of Neurology and Vice Chair of Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York
This educational initiative has been designed for Neurologists, Multiple Sclerosis (MS) specialists, Certified neurology nurse practitioners, and other healthcare professionals who treat patients with MS.
Upon completion of this educational activity, participants will be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of April 1, 2020 through April 1, 2021, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.
Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
Patricia K. Coyle, MD
Consulting Fees: Accordant, Actelion, Alexion, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, TG Therapeutics
Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis
Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The Integrity CE planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.